A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

NCT Number	NCT07218770
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Active Noninfectious Uveitis Affecting the Posterior Segment
Enrollment	72 participants
Start Date	2025-12-17
Primary Completion	2028-06-28 (estimated)
Study Completion	2028-06-28 (estimated)
Updated on ClinicalTrials.gov	2026-04-22